Two Sigma Advisers
HUMA icon

Two Sigma Advisers’s Humacyte HUMA Stock Holding History

Two Sigma Advisers’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-144,100
Closed -$138K – 998
2025
Q4 		$138K Sell
144,100
-99,000
-41% -$140K ﹤0.01% 2175
2025
Q3 		$423K Sell
243,100
-124,000
-34% -$243K ﹤0.01% 1832
2025
Q2 		$767K Buy
367,100
+322,500
+723% +$620K ﹤0.01% 1555
2025
Q1 		$76K Sell
44,600
-102,500
-70% -$385K ﹤0.01% 2278
2024
Q4 		$743K Sell
147,100
-41,300
-22% -$204K ﹤0.01% 1606
2024
Q3 		$1.02M Sell
188,400
-75,900
-29% -$500K ﹤0.01% 1400
2024
Q2 		$1.27M Buy
+264,300
New +$1.38M ﹤0.01% 1428
2024
Q1 		– Sell
-51,200
Closed -$145K – 2527
2023
Q4 		$145K Buy
+51,200
New +$131K ﹤0.01% 2281

Other funds holding HUMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Advisers's HUMA Position: Q1 2026 in Review

Two Sigma Advisers sold out of Humacyte (HUMA) in Q1 2026, closing a stake of 144,100 shares — an estimated $138K sold.

Two Sigma Advisers first reported a position in HUMA in Q4 2023 and held it in 8 quarters. The position peaked at $1.27M in Q2 2024. 159 funds tracked by Wall St. Rank hold HUMA as of Q1 2026.

  • Two Sigma Advisers reported no remaining Humacyte position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 144,100 Humacyte shares in Q1 2026, an estimated $138K.
  • Two Sigma Advisers first reported a position in Humacyte in Q4 2023 and held it in 8 quarters.
  • Two Sigma Advisers's Humacyte position peaked at $1.27M in Q2 2024.
  • 159 funds tracked by Wall St. Rank held Humacyte as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.